[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351508-105":59,"doc-detail-351508-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","eugenoplatin-targets-cancer-stem-cells-through-inhibition-of-the-catenin-signaling-in-triple-negative-breast-cancer-cells","Eugenoplatin targets cancer stem cells through inhibition of the β-catenin signaling in triple-negative breast cancer cells","","Breast cancer remains the leading cause of cancer-related mortality among women worldwide, and the triple-negative subtype shows the worst prognosis. To improve therapy for this aggressive disease, researchers synthesized Eugenoplatin, a phyto-chemo drug conjugate combining cisplatin and eugenol with synergistic anti-cancer activity. Eugenoplatin was characterized by HPLC, LC/MS, and 1H-NMR, evaluated in vitro for cytotoxicity and cellular behavior, and tested in vivo using orthotopic xenografts. Results show enhanced apoptosis induction, cell-cycle delay at G2/M, strong tumor growth inhibition over cisplatin, suppression of β-catenin signaling, STAT3/NF-κB, AKT/mTOR, and ERK, and reduced VEGF-A, IL-6, and IL-8–driven angiogenesis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/eugenoplatin-targets-cancer-stem-cells-through-inhibition-of-the-catenin-signaling-in-triple-negative-breast-cancer-cells/351508/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/eugenoplatin-targets-cancer-stem-cells-through-inhibition-of-the-catenin-signaling-in-triple-negative-breast-cancer-cells/351508.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is Eugenoplatin and what therapeutic goal does it target?","Question",{"text":112,"@type":113},"Eugenoplatin is a phyto-chemo drug conjugate made from cisplatin and eugenol. It is designed to target cancer stem cells by inhibiting the β-catenin signaling pathway in triple-negative breast cancer cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was Eugenoplatin synthesized and characterized?",{"text":117,"@type":113},"Eugenoplatin synthesis and characterization used HPLC, LC/MS, and 1H-NMR. Physicochemical properties were also predicted by in silico analysis using Biovia Discovery Studio.",{"name":119,"@type":110,"acceptedAnswer":120},"What key biological effects were observed in vitro and in vivo?",{"text":121,"@type":113},"Eugenoplatin increased cytotoxicity by inducing apoptosis and caused strong inhibition of cell growth via cell-cycle delay at G2/M. In orthotopic tumor xenografts, it produced more than 10-fold stronger tumor growth inhibition than cisplatin and reduced cancer stem cell biomarkers and angiogenesis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351508,1790119953,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Alraouji et al. Journal of Translational Medicine (2026) 24:577  \n[https://doi.org/10.1186/s12967-026-08007-2](https://doi.org/10.1186/s12967-026-08007-2)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nEugenoplatin (a phyto-chemo drug   \nconjugate) targets cancer stem cells through inhibition of the β-catenin signaling in triplenegative breast cancer cells  \nNoura N. Alraouji 1, Basem Al-Otaibi2, Mohd Yasir Khan3, Falah Al-Mohanna4, Amer Al-Mazrou5, Taher Al-Tweigeri6, Ibrahim Al-Jammaz2, Ayodele A. Alaiya5, Mohammed Cherkaoui3 and Abdelilah Aboussekhra1,7*  \nAbstract  \nBackground Breast cancer is the most prevalent and leading cause of cancer-related mortality among women worldwide. The triple-negative subtype, the most aggressive form of the disease, is associated with the poorest prognosis. In order to improve the treatment of these patients, we have synthesized a phyto-chemo drug conjugate composed of cisplatin and eugenol, two molecules with synergistic anti-cancer effects.  \nMethods Eugenoplatin was synthesized and characterized by HPLC, LC/MS, and 1 H-NMR, while its physicochemical properties were predicted by in silico analysis using the Biovia Discovery Studio. The cytotoxic effects of eugenoplatin were first tested in vitro using the WST1 and the flow cytometry techniques. Cell proliferation, migration, and invasion abilities were assessed using the xCELLigence Real-Time Cell Analysis. The changes in gene expression were determined by proteomics analysis (LC/MS), immunoblotting, immunofluorescence, and quantitative RT-PCR. The effect of the drug on breast cancer stem cells was determined by the tumorsphere formation assay, and cell sorting was utilized to isolate a specific breast cancer sub-population of cells. Furthermore, orthotopic tumor xenografts were used to test the potential therapeutic value of eugenoplatin in vivo.  \nResults The novel DNA-damaging molecule (eugenoplatin) has shown higher cytotoxicity through induction of apoptosis, and strong inhibition of cell growth via cell cycle delay at G2/M phase in different cell lines. In addition, eugenoplatin targeted cancer stem cells through inhibition of the β-catenin signaling pathway. These effects  \nwere confirmed in humanized orthotopic tumor xenografts, wherein the eugenoplatin-dependent tumor growth inhibition was more than 10-fold stronger than the cisplatin repressive effect, with a potent inhibitory effect on cancer stem cell biomarkers. This was associated with the suppression of various cancer-related signaling pathways, including STAT3/NF-κB, AKT/mTOR, and ERK. Furthermore, eugenoplatin down-regulated the pro-angiogenic factors VEGF-A, IL-6, and IL-8, and repressed angiogenesis both in vitro and in tumor xenografts. In silico analysis has suggested good  \n*Correspondence: Abdelilah Aboussekhra[aboussekhra@kfshrc.edu.sa](aboussekhra@kfshrc.edu.sa)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons","cbCaij76E9ymGHnj","https://ap.wps.com/l/cbCaij76E9ymGHnj","pdf",9318546,18,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What is Eugenoplatin and what therapeutic goal does it target?\",\"answer\":\"Eugenoplatin is a phyto-chemo drug conjugate made from cisplatin and eugenol. It is designed to target cancer stem cells by inhibiting the β-catenin signaling pathway in triple-negative breast cancer cells.\"},{\"question\":\"How was Eugenoplatin synthesized and characterized?\",\"answer\":\"Eugenoplatin synthesis and characterization used HPLC, LC/MS, and 1H-NMR. Physicochemical properties were also predicted by in silico analysis using Biovia Discovery Studio.\"},{\"question\":\"What key biological effects were observed in vitro and in vivo?\",\"answer\":\"Eugenoplatin increased cytotoxicity by inducing apoptosis and caused strong inhibition of cell growth via cell-cycle delay at G2/M. In orthotopic tumor xenografts, it produced more than 10-fold stronger tumor growth inhibition than cisplatin and reduced cancer stem cell biomarkers and angiogenesis.\"}]","Eugenoplatin targets cancer stem cells through inhibition of the β-catenin signaling in triple-negative breast cancer cells | PDF",1790094495,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3e6e60e7d1c0b67d0c9a643d0dc5518.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5fa16dca022a49ac933f712a47704fc0.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/feb6c42b86273dadd36317a304a80e11.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f8bb3fe9bfb95e621a2d01180f4820b.webp",980,1306]